Results 1 to 10 of about 20,100 (304)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis [PDF]

Muscle and Nerve, 2019
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN,
Srikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar   +2 more
exaly   +5 more sources

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis

Frontiers in Neurology, 2021
Objective: To investigate the pharmacokinetics, pharmacodynamics, and exposure–response of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with generalized myasthenia gravis (gMG ...
Jonathan P. R. Monteleone, Xiang Gao, Huub Jan Kleijn, Francesco Bellanti, Ryan Pelto   +4 more
exaly   +3 more sources

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

Haematologica, 2010
Background Paroxysmal nocturnal hemoglobinuria is an acquired hemolytic anemia characterized by intravascular hemolysis which has been demonstrated to be effectively controlled with eculizumab.
Anita Hill, Russell P. Rother, Louise Arnold, Richard Kelly, Matthew J. Cullen, Stephen J. Richards, Peter Hillmen   +6 more
doaj   +3 more sources

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]

, 2015
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael, Parikh, MD, Kinjal   +1 more
core   +4 more sources

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

Leukemia Research Reports, 2015
Pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) is associated with increased maternal and fetal morbidity and mortality. There is limited published experience regarding therapy of PNH during pregnancy.
Ruby Sharma, Alla Keyzner, Johnson Liu, Thomas Bradley, Steven L. Allen   +4 more
doaj   +2 more sources

Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies [PDF]

Journal of Comparative Effectiveness Research
What is this summary about? Neuromyelitis optica spectrum disorder (NMOSD for short) is a rare autoimmune health condition, meaning that the body’s natural defense system (the immune system) attacks the body’s own tissues.
Alfredo Damasceno, Mariano Marrodan
doaj   +2 more sources

Safety and Effectiveness of Eculizumab throughout Three Pregnancies in a Patient with Refractory Generalized Myasthenia Gravis: A Case Report [PDF]

Case Reports in Neurology
We describe maternal and fetal outcomes in a patient who had three successful pregnancies while being treated with eculizumab for AChR+ gMG.
Nadia Khalil, Claudia Guerra Hernandez, Jerrica Farias, Kathleen Murray, Niraja Suresh, Clifton Gooch, Tuan H. Vu   +6 more
doaj   +2 more sources

Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome

Frontiers in Pediatrics, 2021
Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS).
Saritha Ranabothu, Clare C. Brown, Richard Blaszak, Rachel Millner, Kristen Rice Moore, Parthak Prodhan   +5 more
doaj   +1 more source

Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report

Case Reports in Neurology, 2021
The recombinant humanized monoclonal antibody eculizumab has been shown to be effective and well tolerated in patients with anti-acetylcholine receptor antibody-positive, treatment-refractory generalized myasthenia gravis (gMG).
Tuan Vu, Brittany Harvey, Niraja Suresh, Jerrica Farias, Clifton Gooch   +4 more
doaj   +1 more source

A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome

Children, 2022
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab.
Saeed AlZabali, Sawsan AlBatati, Khawla Rahim, Hassan Faqeehi, Abubaker Osman, Abdulaziz Bamhraz, Mohammed A. Saleh, Jameela A. Kari, Majed Aloufi, Loai Eid, Haydar Nasser, Abubakr Imam, Entesar AlHammadi, Omar Alkandari, Mohammed Al Riyami, Sidharth Sethi, Christoph Licht, Khalid A. Alhasan, Abdulkarim AlAnazi   +18 more
doaj   +1 more source